Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-12
2010-10-12
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S456000
Reexamination Certificate
active
07812013
ABSTRACT:
Disclosed are compounds of the formula Ior a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or ester thereof, wherein U, W, X, L, Y, M, Z, c, d, e, f, g, h, s, t, R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17and R18are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I.Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1agonist or m2antagonist.
REFERENCES:
patent: 3197476 (1965-07-01), Erner
patent: 3200123 (1965-08-01), Richardson et al.
patent: 5883096 (1999-03-01), Lowe et al.
patent: 5889006 (1999-03-01), Lowe et al.
patent: 5935958 (1999-08-01), Kozlowski et al.
patent: 5952349 (1999-09-01), Asberom et al.
patent: 5977138 (1999-11-01), Wang et al.
patent: 6037352 (2000-03-01), Lowe et al.
patent: 6043255 (2000-03-01), Lowe et al.
patent: 6066636 (2000-05-01), Kozlowski et al.
patent: 6294554 (2001-09-01), Clader et al.
patent: 6458812 (2002-10-01), McKittrick et al.
patent: 2003/0004353 (2003-01-01), Yasuda et al.
patent: 2006/0281729 (2006-12-01), Iserloh et al.
patent: 2007/0072852 (2007-03-01), Zhu et al.
patent: 0 682 025 (1995-11-01), None
patent: 2 741 072 (1997-05-01), None
patent: 2 747 678 (1997-10-01), None
patent: WO 90/15058 (1990-12-01), None
patent: WO 01/16136 (2001-03-01), None
patent: WO 02/074719 (2002-09-01), None
patent: WO 03/031412 (2003-04-01), None
patent: WO 2005/003106 (2005-01-01), None
patent: WO 2005/058311 (2005-06-01), None
patent: WO 2006/116412 (2006-11-01), None
patent: WO 2007/092839 (2007-08-01), None
Vippagunta et al. Advanced Drug Delivery Reviews, 2001, 48, 3-26.
Balaban, Teodor Silviu, et al., “2-Aminopyrimidine Directed Self-Assembly of Zinc Porphyrins Containing Bulky 3,5-Di-tert-butylphenyl Groups”, Journal of the American Chemical Society (2003), 125(14), 4233-4239; 2003:215204 (Abstract).
Brown, George Barremore, “Atelopidtoxin. Purification and Chemistry”, University Microfilms, Ann Arbor, Order No. 73-4474 (1972) 186 pp.; 1973:401115 (Abstract).
Brownlee, T.C., et al., “Infrared absorption of substituents in heterocyclic systems. X. Amine-imine tautomerism by infrared spectroscopy: Further examples”, Journal of the Chemical Society [Section] B: Physical Organic (1966), (8), 726-7; 1966:465084 (Abstract).
Coppola, Gary M., “Novel heterocycles. I. Synthesis and reactions of 6,7-dihydro-1H, 3H,5H-pyrido[3,2,1-ij][3,1]benzoxazine-1,3-dione”, Journal of Heterocyclic Chemistry (1978), 15 (4), 645-7; 1979:22931 (Abstract).
Drusvyatskaya, S.K., et al., “Synthesis and anthelmintic properties of pyrimidinoperimidines”, Khimiko-Farmatsevticheskii Zhurnal (1983), 17(2), 158-60; 1983:198150 (English Abstract).
Fuhrman, Frederick A., et al., “Toxin from skin of frogs of the genusAtelopus; differentiation from dendrobatid toxins”, Science (Washington, DC, United States) (1969), 165(3900), 1376-7; 1969:521925 (Abstract).
Golubushina, G.M., et al., “Condensation of 2-amino-3,4,5,6-tetrahydroimidazo [4,5,1-ij]quinoline and 2-amino-2-pyrrline with β-diketones”, Khimiya Geterotsiklicheskikh Soedinenii (1972), (3), 419-21; 1972:488425 (English Abstract).
Henderson, R., et al., “Binding of labeled saxitoxin to the sodium channels in nerve membranes”, Journal of Physiology (Cambridge, United Kingdom) (1973), 235(3), 783-804; 1974:116904 (Abstract).
Huang, Minta, et al., “Accumulation of cyclic adenosine monophosphate in incubated slices of brain tissue. 2. Effects of depolarizing agents, membrane stabilizers, phosphodiesterase inhibitors, and adenosine analogs”, Journal of Medicinal Chemistry (1972), 15(5), 462-6; 1972:443058 (Abstract).
Iwamoto, Osamu, et al., “Total synthesis of (−)-decarbamoyloxysaxitoxin”, Angewandte Chemie, International Edition (2007), 46(45), 8625-8628; 2007:1398087 (Abstract).
Kim, Yong Hae, et al., “Potent Neurotoxins: Tetrodotoxin, Chiriquitoxin, and Zetekitoxin fromAtelopusFrogs in Central America”, Journal of Toxicology, Toxin Reviews (2003), 22(4), 521-532; 2003:985614 (Abstract).
Kukla, Michael J., et al., “Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)-one (TIBO) derivatives”, Journal of Medicinal Chemistry (1991), 34(11), 3187-97; 1991:632195 (Abstract).
Mari, Yotsu-Yamashita, et al., “The structure of zetekitoxin from the Panamanian frogAtelopus zeteki”, Tennen Yuki Kagobutsu Toronkai Koen Yoshishu (2000), 42nd, 415-420; 2001:101914 (English Abstract).
Mitsumi, Minoru, et al., “Three-dimensional H-bonded networks based on mono- and tetranuclear metal-pteridine complexes”, Molecular Crystals and Liquid Crystals Science and Technology, Section A: Molecular Crystals and Liquid Crystals (1996), 276, 229-235; 1996:295932 (Abstract).
Nagamatsu, Kentaro, et al., “Reactions of 8-(triphenylphosphoimino)quinoline with aryl aldehydes and aryl isocyanates: formation of 2-aryl-4H-imidazo[4,5,1-1-ij]quinolines and related systems”, Heterocycles (2006), 69, 167-178; 2007:16172 (Abstract).
Poludnenko, V.G., et al., “Derivatives of 5,6-dihydro-4H-imidazo[4,5,1-i,j]quinoline. I. Synthesis and reactions of 2-amino derivatives”, Khimiya Geterotsiklicheskikh Soedinenii (1970), (10), 1410-13; 1971:53657 (English Abstract).
Pozharskii, A.F., et al., “Heterocyclic analogs of pleiadiene. 53. Properties of 1,9-trimethyleneperimidine”, Khimiya Geterotsiklicheskikh Soedinenii (1981), (7), 980-2; 1981:603864 (English Abstract).
Price, Clayton, et al., “Macrochelation, cyclometallation and G-quartet formation: N3-and C8-bound Pdll complexes of adenine and guanine”, Chemistry—A European Journal (2001), 7(6), 1194-1201; 2001:240418 (Abstract).
Richardson, Alfred, Jr., “The synthesis and chemistry of certain 2-substituted 5,6-dihydroimidazo-,-oxazolo-, and—thiazolo[ij]quinolines”, Journal of Organic Chemistry (1963), 28(10), 2581-7; 1963:462271 (Abstract).
Roseen, Jill S., et al., “Comparison of the effects of atelopidtoxin with those of tetrodotoxin, saxitoxin, and batrachotoxin on beating of cultured chick heart cells”, Toxicon (1971), 9(4), 411-15; 1972:21760 (Abstract).
Shindelman, Jeffrey, et al., “Atelopidtoxin from the Panamanian frog,Atelopus zeteki”, Toxicon (1969), 7(4), 315-19; 1970:98699 (Abstract).
Simonov, A.M., et al., “Amination of 5,6-dihydro-4H-imidazo[4,5,1-i,j]quinoline”, Khimiya Geterotsiklicheskikh Soedinenii (1969), (3), 567; 1969:524323 (English Abstract).
Simonov, A.M., et al., “Derivatives of 5,6-dihydro-4H-imidazo[4,5,1-i,j]quinoline. III, Substitution reactions in a 5,6-dihydro-4H-imidazo[4,5,1-i-j]quinoline series”, Khimiya Geterotsiklicheskikh Soedinenii (1972), (2), 242-6; 1972:140645 (English Abstract).
Vilar, Santiago, et al., “Probabilistic Neural Network Model for the In Silico Evaluation of Anti-HIV Activity and Mechanism of Action”, Journal of Medicinal Chemistry (2006), 49(3), 1118-1124; 2006:44967 (Abstract).
Werbel, Leslie M., et al., “Synthesis of 5,6,-dihydro-8-methoxy-4H-imidazo[4,5,1,-ij] quinolines and some related ring systems”, Journal of Heterocyclic Chemistry (1968), 5(3), 371-8; 1968:436031 (Abstract).
Berge, Stephen M., et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 1977, pp. 1-19; vol. 66, Issue 1.
Byoung-Kuk, Na, et al., “Aspartic proteases of Plasmodium vivax are highly conserved in wild isolates”, The Korean Journal of Parasitology, 2004, pp. 61-66, vol. 42, No. 2.
Gould, Philip L., “Salt selection for basic drugs”, Internati
Iserloh Ulrich
Stamford Andrew
Voigt Johannes H.
Zhu Zhaoning
Jarrell Noble
Lee William Y.
MacMillan Keith D.
Schering Corporation
Wilson James O
LandOfFree
Macrocyclic heterocyclic aspartyl protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrocyclic heterocyclic aspartyl protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic heterocyclic aspartyl protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4235963